Enfortumab vedotin- and/or pembrolizumab-related AEs
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Pharmacovigilance and Adverse Drug Reactions
Bladder and Urothelial Cancer Treatments
Publication details
- Journal / source
- Reactions Weekly
- Volume
- 2096
- Issue
- 1
- Pages
- 7–7
- Publication date
- 6 February 2026
- Language
- EN